Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Guardant and Pfizer will use liquid biopsy tests in global oncology clinical trials ... testing capabilities in China through an existing partnership with Adicon Holdings. Feel unsure about ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

A Legacy of Innovation in Philippine, Global Health care Pfizer Philippines had a multitude ... about the importance of vaccination and partnerships with key hospitals and government bodies ...

Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...

and global Pfizer RWE leaders to explore the potential of Abu Dhabi’s Trusted Research Environment in advancing scientific discovery. This initiative is part of a broader effort under the MoU to ...

Revolve Wealth Partners LLC lifted its holdings ... analysts have recently commented on the stock. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday ...

While gaps persist in workforce retention, infrastructure, and equitable access, the transformation of Nigeria’s health ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...